Exosome therapy questions, answered

A tiny particle released by a living cell, one class of what biologists call extracellular vesicles. It carries cargo from its parent cell - proteins, lipids, signalling molecules and RNA including microRNA - and delivers those messages to other cells.

Treatment with a prepared concentrate of those particles. It contains no living cells, which is why it is sometimes planned where a cell product is not the right fit, and it is applied or injected by a clinician using the route your plan names.

No. A cell product contains living cells; an exosome preparation contains the signalling particles cells release. Our stem cells and exosomes comparison sets the two side by side, including how each is prepared and given.

Skin and scalp procedures, local injections around joints and tendons, and intravenous administration where the goal is more general. Each of those is planned separately, with its own target, its own measure and its own consent.

These are among the most researched applications and a large part of what patients ask us about. Our team starts with the cause of the hair thinning or the skin concern, records a photographic baseline, and sets a goal that photographs at the review point can actually show.

Inflammatory signalling around a joint or tendon is one of the main research questions behind musculoskeletal use. We plan it from your imaging and examination, and it is often discussed alongside a targeted injection so the preparation reaches the structure causing the symptoms.

As a skin or scalp procedure, as a local injection into or beside a joint or tendon, or as an intravenous infusion. The route follows the goal rather than preference, and no route is presented as better than another.

Sessions are planned from what the review shows rather than booked as a standing course. Your plan states what is proposed at the start, what we will look at afterwards, and when a further session would be considered.

Possible effects depend on the route and the individual, and include reactions at the treated area, temporary redness or swelling, and procedure-related risks such as infection at the site. Your plan lists what applies to you, what we monitor for, and who to contact afterwards.

Rules for cell-derived preparations differ between countries. Our medical team answers this directly for the preparation planned for you, covering where it comes from, how it was produced and characterised, and the testing it passed before release, in writing before you agree to treatment.

That depends on the area treated, the goal set and the individual, so we describe it for your case rather than as a general figure. Recording a baseline beforehand is what makes the review afterwards meaningful.

The two are sometimes planned together, and sometimes one alone is the better answer. Our cell treatment uses mesenchymal stromal cells from Wharton's jelly inside a donated umbilical cord; an exosome preparation delivers signalling particles and no cells at all. Our medical team explains what each component is there for, prices them separately, and is clear that you can take one without the other.